The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1687
October 16, 2023
View Complete Issue         Table of Contents 2019 
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
October 16, 2023 (Issue: 1687)
The FDA has approved an intranasal formulation of the opioid antagonist nalmefene (Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene, which is available by prescription, is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
Article code: 1687b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.